Bristol Myers Squibb’s 4.3% Dividend Yield: Safe or at Risk?

Bristol Myers Squibb (BMY) offers a dividend yield of 4.3%, which is higher than the average for large pharmaceutical companies. Investors often ask if this payout is safe. The answer depends on the company’s cash flow and debt. The drugmaker generates strong cash from its key medicines, including Eliquis and Opdivo. However, both drugs face patent expirations in the coming years. This could reduce future revenue. To offset this, Bristol Myers is cutting costs and buying smaller biotech firms to find new growth. The company’s dividend payout ratio is about 60% of its earnings. This is considered manageable. But its debt level is high after recent acquisitions. If new drugs fail to replace lost sales, the company may need to cut spending or reduce the dividend. For now, the dividend appears secure. Investors should watch for updates on new drug approvals and patent challenges. Any major setback could change the outlook.